Every Form 4 that Becton, Dickinson and Co. (BDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDX filings page.
BECTON DICKINSON & CO (BDX) reported that EVP & Chief Financial Officer Vitor Roque had 190 shares of common stock withheld on September 2, 2026 to pay withholding taxes upon vesting of previously reported restricted stock unit awards. This was not an open-market sale. After this tax-withholding transaction, Roque directly holds 8,041 shares of BDX common stock.
BECTON DICKINSON & CO (BDX) executive Michael Feld, EVP and Chief Revenue Officer, reported a sale of 165 shares of common stock on August 26, 2026 at $188.49 per share in an open market or private transaction. After this transaction, he directly holds 19,720 shares of BDX common stock. The company notes the trade was made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.
BECTON DICKINSON & CO (BDX) reported an insider tax-related share withholding by executive officer Michael Feld, EVP and Chief Revenue Officer. On 2026-08-20, Feld had 1,049 shares of common stock withheld to pay withholding taxes in connection with the vesting of previously reported restricted stock unit awards. Following this transaction, Feld directly held 19,885 shares of BDX common stock. The event reflects tax withholding rather than an open-market purchase or sale.
Becton Dickinson & Co. Chairman, CEO and President Thomas E. Polen Jr. exercised 43,278 Stock Appreciation Rights on August 13, 2026 at a conversion price of $167.25 per share, receiving an equal number of common shares, then returned 39,126 shares to the issuer and sold 4,152 shares at $185.00 per share. These transactions were made pursuant to a Rule 10b5-1 plan adopted on March 2, 2026.
Becton Dickinson & Co executive Roland Goette, EVP and President, EMEA, reported selling 2,438 shares of Common Stock on August 11, 2026 in an open market or private transaction at $180.84 per share. The shares sold were acquired through the company’s Global Share Investment Program (GSIP). Following this sale, Goette held 14,856 shares directly, with these holdings reflecting the addition of dividends received as part of an equity adjustment tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. He also held 1,779 shares indirectly through a GSIP Trust as of August 3, 2026.
Becton Dickinson director Robert Luther Huffines acquired 189 rights to common stock under the BD Deferred Compensation Plan on 2026-08-06, credited at $165.62 per right. Each right converts into one share of common stock and is distributed after his board service ends or on dates he specifies. After this award, he directly holds 595 rights, including amounts accumulated through dividend investment.
Becton Dickinson director Carrie L. Byington received a grant of 94 rights to Common Stock under the BD Deferred Compensation Plan at a reference price of $165.62 per right. Each right converts one-for-one into Common Stock, bringing her total plan rights to 3,810, including rights added through dividend investment since her last report.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of Common Stock on 2026-07-27 at $157.1300 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on February 7, 2025, and Feld now holds 20,934 shares directly.
Becton Dickinson executive Muhsin Bilal reported routine equity compensation activity. He received 14,342 shares of Common Stock as a restricted stock unit award under the company’s 2004 equity-based compensation plan. In a separate entry, 1,935 shares were withheld to cover taxes upon RSU vesting. After these transactions, he directly holds 41,359 shares of Becton Dickinson common stock.
Becton Dickinson & Co executive Michael Feld reported a small stock sale. On June 26, 2026, the EVP and Chief Revenue Officer sold 75 shares of Common Stock in an open-market transaction at $152.80 per share. After this sale, he directly owns 21,009 shares of the company’s stock.
Becton Dickinson executive Michael David Garrison reported an open-market sale of company stock. On this Form 4, he sold 1,100 shares of Becton Dickinson common stock at a price of $145.66 per share. After the transaction, he directly owns 13,172 shares of common stock.
Becton Dickinson & Co executive Michael David Garrison reported an open-market sale of company stock. On June 10, 2026, he sold 1,100 shares of Common Stock at an average price of $151.48 per share. After this transaction, he directly holds 14,272 shares. A footnote explains that his direct holdings reflect prior adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the number of shares underlying previously reported, unvested time-vested restricted stock units.
Becton Dickinson & Co. Chairman, CEO and President Thomas E. Polen Jr. reported several transactions in company common stock. He sold 2,764 shares in an open-market sale at a weighted average price of $146.35 per share, with actual prices ranging from $145.21 to $147.49. He also disposed of 17,445 shares to the issuer at $146.15 per share and exercised stock appreciation rights covering 20,209 shares at an exercise price of $126.16 per share, receiving the underlying common stock. After these moves, he continues to hold over 100,000 shares directly, indicating that the transactions represent a partial, not complete, change in his equity position.
Menziuso Peter reported acquisition or exercise transactions in this Form 4 filing.
Becton Dickinson & Co. executive Peter Menziuso, EVP and President, BDI, received a grant of 14,258 shares of Common Stock on June 1, 2026. The award is in the form of restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan and carries no purchase price.
Following this compensation-related grant, Menziuso directly holds 14,258 shares of Becton Dickinson common stock. This is an equity incentive award rather than an open-market share purchase or sale.
Becton Dickinson & Co Executive Vice President and Chief Revenue Officer Michael Feld sold 75 shares of Common Stock in an open-market transaction at $147.35 per share. After this sale, he directly holds 21,084 shares of the company.
Becton Dickinson & Co director Robert Luther Huffines received 210 derivative rights to common stock under the BD Deferred Compensation Plan. The rights were granted at a reference price of $149.04 per right and increase his total deferred rights to 404.
Each right converts into one share of common stock, and the securities are distributed after his service as a director ends or on dates he previously specified. The total also reflects rights acquired through dividend reinvestment and adjustments related to combining the Biosciences and Diagnostic Solutions businesses with Waters Corp.
Becton Dickinson & Co director Carrie L. Byington received 105 rights to common stock under the BD Deferred Compensation Plan as a compensation-related derivative award. Each right converts into one share of common stock, bringing her total deferred stock rights to 3,699 after this grant.
Becton Dickinson & Co EVP & Chief Financial Officer Vitor Roque received an equity grant. He acquired 1,721 shares of Common Stock on May 7, 2026 through a grant or award at a reported price of $0.00 per share. After this award, he directly holds 8,231 shares, which include restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, reported an open-market sale of 74 shares of Common Stock at $151.94 per share. After this transaction, he directly holds 21,159 shares of Becton Dickinson common stock, according to the filing.
Becton Dickinson & Co executive Neal Shana Carol reported a tax-related share withholding tied to equity compensation. On this Form 4, 1,146 shares of common stock were withheld to cover withholding taxes upon vesting of previously granted restricted stock units. After this non-market disposition, Carol directly holds 23,966 common shares. The filing also notes that direct holdings reflect adjustments connected to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the number of shares underlying previously reported unvested time-based restricted stock units.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of common stock at $156.83 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. After this planned sale, he directly owns 21,233 shares.
Becton Dickinson & Co executive Lanesha Minnix received an equity award of 7,492 shares of Common Stock on March 16, 2026. The Form 4 classifies this as a grant or award acquisition at no purchase price. A footnote explains the award represents restricted stock units granted under the company’s 2004 equity-based compensation plan. Following this grant, Minnix directly holds 7,492 shares.
Becton Dickinson & Co. interim CFO Vitor Roque reported receiving a grant of 931 shares of common stock on March 2, 2026, at a stated price of $0.00 per share as a stock award. After this acquisition, his directly held stake increased to 6,510 common shares. A footnote explains that his direct holdings reflect adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
BECTON DICKINSON & CO senior vice president, controller and chief accounting officer Pamela L. Spikner reported an acquisition of 931 shares of common stock as a grant or award at a price of $0.00 per share. Following this transaction, her directly held stake is 3,323 common shares.
A footnote explains that her direct holdings reflect adjustments tied to the combination of the company’s Biosciences and Diagnostic Solutions businesses with Waters Corp., affecting the number of shares underlying previously reported, unvested time-vested restricted stock units.
Becton Dickinson & Co EVP and Chief Revenue Officer Michael Feld sold 75 shares of common stock in an open-market transaction at $181.84 per share. After this sale, he directly holds 21,308 shares. A footnote notes prior adjustments to his direct holdings tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
Becton Dickinson & Co director Scott L. Bertram reported an open-market sale of common stock. On February 18, 2026, he sold 953 shares at an average price of $182.61 per share. After this transaction, he directly owns 36,763 shares of Becton Dickinson common stock.
Becton Dickinson & Co, a 10% owner of Augusta SpinCo Corp, reported a large share distribution. On February 9, 2026, it distributed 284,771,350 shares of Augusta common stock to its own public stockholders for no consideration, on a pro rata basis, under a prior separation agreement.
After this transaction, Becton Dickinson reported owning zero Augusta shares, indicating it no longer held a direct equity stake in Augusta SpinCo Corp.
Becton, Dickinson and Company director Robert Luther Huffines reported an acquisition of deferred stock rights. On February 4, 2026, he acquired 100 derivative securities described as rights to common stock under the BD Deferred Compensation Plan at a price of $201.91 per right, and now beneficially owns 100 such rights directly.
The rights convert into Becton Dickinson common stock on a one-for-one basis. According to the plan terms, these securities are distributed after his service as a director ends, or on the date or dates he specifies.
Becton, Dickinson and Company director Carrie L. Byington reported acquiring 30 derivative rights to common stock under the BD Deferred Compensation Plan on 02/04/2026. These rights are valued at $201.91 per underlying share and convert into common stock on a one-for-one basis.
Following this transaction, Byington beneficially owns a total of 1,714 rights, held directly. The rights are scheduled to be distributed after her service as a director ends, or on dates she specifies in advance, and the total includes rights gained through dividend reinvestment.
Becton, Dickinson and Company director Christopher Ian Montague Jones acquired additional deferred stock rights under the BD Deferred Compensation Plan. On February 4, 2026, he acquired 272 rights to common stock at a reference price of $201.91 per right. Each right converts into one share of BD common stock. Following this transaction, he beneficially owns 11,649 derivative securities representing rights to BD common stock, held directly. These securities are scheduled to be distributed after his service as a director ends, or on dates he has previously specified, and the total includes rights accumulated through dividend reinvestment.
Becton, Dickinson and Company director Jeffrey W. Henderson reported an equity award of company stock. On 01/27/2026, he received 1,098 shares of common stock in the form of restricted stock units granted under the 2004 Employee and Director Equity-Based Compensation Plan at a stated price of $0 per share.
After this award, Henderson beneficially owns 9,143 shares of Becton Dickinson common stock directly, plus 15 shares held indirectly by his wife. The filing notes that his total includes units acquired through dividend reinvestment since his prior report.
Becton, Dickinson and Company director R. Andrew Eckert received 1,098 shares of common stock on January 27, 2026 through an award of restricted stock units. The units were granted at a price of $0 per share under the company’s 2004 Employee and Director Equity-Based Compensation Plan and include amounts from dividend reinvestment. After this award, Eckert beneficially owned 10,423 shares of Becton Dickinson common stock in direct form.
Becton, Dickinson and Company director Carrie L. Byington received 1,098 shares of common stock on January 27, 2026 through a stock-based award. The shares were acquired at a price of $0 per share, reflecting a grant rather than an open-market purchase.
The award represents restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, including units accumulated through dividend reinvestment. Following this transaction, Byington beneficially owns 5,018 shares of Becton Dickinson common stock in direct ownership.
Becton, Dickinson and Company director Gregory Hayes received an equity award in the form of restricted stock units. On 01/27/2026 he was awarded 1,098 common shares at a price of $0 per share, reported as an acquisition. These units were granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan and include amounts accumulated through dividend reinvestment since his last report. Following this award, Hayes beneficially owns 7,159 shares of Becton Dickinson common stock in direct form.
Becton Dickinson director William M. Brown reported a new stock-based award. On 01/27/2026, he acquired 1,098 shares of Becton Dickinson common stock at a price of $0 per share, reported as an "A" (award) transaction. Following this grant, he beneficially owned 4,663 shares, held directly.
The filing notes that the 1,098 shares represent restricted stock units granted under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan, and that the total includes units acquired through dividend investment since his last report.
Becton, Dickinson and Company director Robert Luther Huffines received 1,098 shares of common stock in the form of restricted stock units on January 27, 2026. The units were awarded at a price of $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this grant and units accumulated through dividend reinvestment since his last report, Huffines now beneficially owns 1,279 shares of Becton Dickinson common stock in direct form.
Becton, Dickinson and Company director Christopher Ian Montague Jones received 1,098 shares of common stock on January 27, 2026 as an equity award at a price of $0 per share. These shares were granted in the form of restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this transaction, Jones beneficially owned 24,304 shares of Becton Dickinson common stock in direct form. The total includes units that were added through dividend reinvestment since his prior ownership report.
Becton Dickinson director Timothy M. Ring reported an equity award in the form of restricted stock units. On January 27, 2026, he acquired 1,098 shares of common stock at $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this award, Ring beneficially owned 59,160 shares of Becton Dickinson common stock directly, plus 2,285 shares indirectly through a 401(k) plan, which includes units accumulated from dividend reinvestment since his prior report.
Becton, Dickinson and Company director Bertram L. Scott received 1,098 shares of common stock on January 27, 2026, at a price of $0 per share. The filing explains this represents restricted stock units awarded under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this grant, Scott beneficially owned 37,716 shares directly, which include units acquired through dividend investment since his last report.
Becton, Dickinson and Company director Joanne Waldstreicher received 1,098 shares of common stock in the form of restricted stock units on January 27, 2026. The units were granted at a price of $0 under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Following this grant and units acquired through dividend reinvestment since her last report, Waldstreicher beneficially owns 3,391 shares of Becton Dickinson common stock in direct ownership. This filing reflects equity-based compensation rather than an open-market purchase.
Becton, Dickinson and Company director Jacqueline Wright reported an equity award of 1,098 shares of common stock on January 27, 2026. The award was granted at a price of $0 per share as restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
After this grant and including units acquired through dividend reinvestment since her last report, Wright beneficially owns 1,279 common shares in direct form. This filing reflects routine director compensation in the form of equity awards rather than an open-market purchase.
Becton, Dickinson and Company executive Michael Feld, EVP, CRO & President of Life Sciences, reported selling 75 shares of BDX common stock on January 26, 2026 at a price of $202.73 per share. Following this sale, he directly beneficially owns 16,431 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025.
Becton, Dickinson and Company senior vice president, controller and chief accounting officer Pamela L. Spikner reported a routine share withholding related to equity compensation. On January 21, 2026, 84 shares of common stock were withheld at a price of $0.00 per share to cover withholding taxes tied to the vesting of previously granted restricted stock units. After this tax-withholding transaction, Spikner directly beneficially owned 1,832 shares of Becton Dickinson common stock.
Becton Dickinson & Co executive Michael David Garrison reported multiple stock transactions. On 01/15/2026, he exercised 3,054 stock appreciation rights at an exercise price of $167.91 per share, receiving 3,054 shares of common stock. He then disposed of 2,454 shares at $209 per share and sold 600 additional shares at $209 and 1,010 shares at $206.54.
After these transactions, he directly owned 12,095 shares of Becton Dickinson common stock. The filing notes that the reported transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
Becton Dickinson & Co. executive vice president and Chief ISC Officer David Shan reported a routine share withholding related to equity compensation. On 01/03/2026, 44 shares of Becton Dickinson common stock were withheld at a price of $0 to cover taxes due on the vesting of previously reported restricted stock unit awards. After this transaction, Shan beneficially owns 8,926 shares of common stock in direct ownership.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.
Becton Dickinson & Co executive Michael David Garrison reported selling 629 shares of common stock at $196.03 per share on December 17, 2025. After this sale, he directly owns 13,105 shares.
Garrison serves as EVP & Pres Med.Essntl&BioPharm, and the sale was made under a Rule 10b5-1 plan he adopted on August 13, 2025.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock. On 12/01/2025, he sold 75 shares of Becton Dickinson common stock at a price of $193.36 per share. After this transaction, he beneficially owned 16,580 shares of Becton Dickinson common stock in direct ownership. The filing notes that this sale was made under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Becton, Dickinson and Company reported an insider equity award for director Jacqueline Wright. On 12/01/2025, she acquired 180 shares of common stock through a grant of restricted stock units under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. The Form 4 shows the transaction as an acquisition at a stated price of $0, reflecting a stock-based compensation award rather than an open-market purchase. Following this grant, she beneficially owned 180 shares, held directly.
Becton, Dickinson and Company director reports stock award. A company director filed a Form 4 reporting the acquisition of 180 shares of Becton Dickinson common stock on 12/01/2025. The filing shows the transaction code "A," indicating an acquisition, at a price of $0 per share, and lists 180 shares beneficially owned directly after the transaction.
The footnote explains that these 180 shares represent restricted stock units granted under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. This reflects routine equity-based compensation rather than an open-market purchase or sale.